Hemostemix Inc
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Thomas A. Smeenk
- Full Time Employees
- 12
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 707-7th Avenue SW Calgary AB Canada T2P 3H6
- IPO Date
- Dec 20, 2012
- Website
- hemostemix.com
- Similar Companies
- Business
- Hemostemix Inc. (TSXV:HEM) develops, manufactures and commercializes autologous stem cell therapies derived from patients' own blood for treating ischemic diseases including critical limb threatening ischemia, peripheral arterial disease, angina, ischemic cardiomyopathy and dilated cardiomyopathy; its lead product ACP-01 comprises angiogenic cell precursors that migrate to ischemic areas, embed in damaged tissues, release growth factors, reduce inflammation and generate new blood vessels to restore oxygen and nutrient flow; the company also advances NCP-01 in preclinical development for neuropathic pain and motor function recovery, alongside a patented Automated Cell Therapy System (ACTS) robotics platform in partnership with manufacturing ally CytoImmune Therapeutics to scale production up to 23,040 therapies annually. Founded in 2006 and headquartered in Calgary, Alberta, Canada, Hemostemix operates primarily in North America with expansion interests in regions like Puerto Rico and the Dominican Republic, targeting no-option patients underserved by conventional revascularization. In June 2024, the company entered a strategic manufacturing partnership with CytoImmune Therapeutics including a funded services agreement and $1.8 million in financing commitments to restart ACP-01 production for physician-ordered treatments; it closed this deal in August 2024 to enable initial batches and ramp sales targeting $2 million monthly by 2025; most recently in November 2025, Hemostemix initiated a roll-up of cardiology practices by acquiring interests in two Dominican Republic interventional cardiologist groups to secure patient streams and integrate ACP-01 deliveries.
Company News
Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update
Hemostemix to Attend Centurion One Capital's 4th Annual Bahamas Summit
Hemostemix Non Brokered Private Placement
Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA
Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial
Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026
Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results
Hemostemix Grants Stock Options
Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain
Hemostemix Closes $360,000 First Tranche of Private Placement
Hemostemix' $1,000,000 Private Placement and Update
Hemostemix Leadership Attending Abundance360 Summit
Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships
Hemostemix Receives FDA Support for Its Basket Protocol Approach
Hemostemix Closes $480,000 Private Placement at $0.12 per Share
Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01
Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv)
Hemostemix Grants Stock Options
Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000
Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations